医学
阿替唑单抗
膀胱癌
肿瘤科
芽孢杆菌(形态)
内科学
泌尿科
卡介苗
临床试验
外科
临床研究阶段
随机对照试验
膀胱
膀胱肿瘤
不利影响
癌症
作者
Morgan Rouprêt A,Aurélie Bertaut,G. Pignot,Y. Neuzillet,Nadine Houédé,Romain Mathiéu,Luc Corbel,D. Besson,Thomas Seisen,Loïc Jaffrelot,Cedric Michel Lebacle,Stéphane Champiat,Souhil Lebdai,Marc‐Olivier Timsit,Constance Thibault,Lieven Goeman,Á. Juárez Soto,C. La,C. Léger,Yohann Loriot
标识
DOI:10.1016/j.annonc.2025.09.017
摘要
BACKGROUND: Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30%-40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure. PATIENTS AND METHODS: The ALBAN trial is an international, 1 : 1 randomized, open-label phase III trial comparing the combination of atezolizumab (an anti-PD-L1 antibody) and BCG (arm B) versus BCG alone (arm A) for BCG-naive patients with high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS). Key secondary endpoints included high-grade recurrence-free survival, complete response rate, and duration of response in patients with carcinoma in situ disease, as well as overall survival. RESULTS: In total, 255 patients were randomly assigned to arm A and 262 to arm B. The trial did not meet its primary endpoint; there was no significant difference in EFS between arms, with a hazard ratio of 0.98 (95% confidence interval 0.71-1.36, P = 0.9106). EFS results were consistent across all prespecified subgroups. The safety profile of the treatment combination was consistent with that of the individual agents but showed higher rates of treatment-related adverse events (TRAEs) and grade ≥3 TRAEs than BCG alone. CONCLUSION: This phase III trial in BCG-naive patients with high-risk NMIBC did not demonstrate an EFS benefit from the addition of atezolizumab to 1-year BCG therapy, in contrast to positive EFS results reported with another PD-(L)1 agent, suggesting that any benefit from checkpoint-BCG therapy may be context- and agent-specific rather than a class effect. Future research should focus on biomarker-driven patient selection and optimization of the timing, duration, and route of checkpoint delivery relative to BCG.
科研通智能强力驱动
Strongly Powered by AbleSci AI